An G et al., 2019-04: First-in-human phase 1 study of oxfendazole, in 70 healthy volunteers, randomised against placebo at single oral doses from 0.5 to 60 mg/kg.
Seventy subjects were randomly assigned to receive a single oral dose of oxfendazole (0.5, 1, 3, 7.5, 15, 30, or 60 mg oxfendazole/kg body weight) or placebo and were followed for 14 days.
An G et al., 2019-04: First-in-human phase 1 study of oxfendazole, in 70 healthy volunteers, randomised against placebo at single oral doses from 0.5 to 60 mg/kg. Study type: randomised, placebo-controlled, single ascending dose phase 1 trial. N=70 (56 oxfendazole, 14 placebo). Country: United States (University of Iowa Clinical Research Unit). Route: oral. Dose: 0.5, 1, 3, 7.5, 15, 30, 60 mg/kg single dose; 14-day follow-up. Comparator: placebo. Funder: Division of Microbiology and Infectious Diseases, NIAID/NIH, via Vaccine and Treatment Evaluation Unit contracts HHSN272200800008C and HHSN272201300020I, plus NCATS grant 5U54TR001356 to the University of Iowa. Conflicts: no conflict-of-interest statement found in the PMC text. Drug product maker/supplier: not named in the PMC text. Registered NCT02234570. PMID 30745383. IMPORTANT SCOPE NOTE: this is oxfendazole, not fenbendazole; a human oxfendazole trial is not evidence of fenbendazole's human safety or efficacy. Author list corrected to the PubMed/Europe PMC author string for PMID 30745383 (first author An G, not Bach T). Context: oxfendazole and fenbendazole interconvert metabolically (EMA/JECFA); this is the closest regulated human dosing data in the fenbendazole family. Study type: randomized trial.
